C-peptide Seen as Key Biomarker for Type 1 Diabetes Drug Trials
May 03, 2026
C-peptide is described as a key biomarker for beta cell function in type 1 diabetes and a potential surrogate endpoint for drug approval. Current trial endpoints remain difficult for disease-modifying therapies.